Form 4: OnKure Therapeutics CEO Sells Shares to Cover Tax Obligations
Insider Transaction Report
OnKure Therapeutics, Inc. President and CEO, Nicholas A. Saccomano, sold 88 shares of Class A Common Stock to satisfy tax withholding obligations related to RSU vesting.
Summary
- Nicholas A. Saccomano, who serves as President and CEO and a Director of OnKure Therapeutics, Inc. (OKUR), reported a transaction on June 23, 2025.
- He disposed of 88 shares of the company's Class A Common Stock at a weighted average sale price of $2.3842 per share.
- The sale was an automatic transaction executed to cover tax withholding obligations incurred from the vesting of restricted stock units (RSUs), as per the terms of the Issuer's 2023 RSU Equity Incentive Plan.
- Following this reported transaction, Mr. Saccomano's beneficial ownership stands at 3,594 shares, which includes certain RSUs.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations upon RSU vesting, which is a neutral event and does not indicate positive or negative sentiment regarding the company's prospects.
Industry Context
This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries when executive compensation includes restricted stock units. It does not provide broader industry insights.
Related Party Transactions
- The transaction involves the sale of shares by a corporate officer (Nicholas A. Saccomano) to cover tax obligations arising from the vesting of company-issued restricted stock units, which is a common form of related party transaction in executive compensation.
Stakeholder Impact
- Shareholders: The sale of a small number of shares for tax purposes is unlikely to have a material impact on the share price or existing shareholder value.
- Employees: The transaction reflects a standard component of executive compensation, which is common practice in many companies.
Key Dates
| Date | Description |
|---|---|
| 06/23/2025 | Date of earliest transaction (sale of shares) |
| 06/25/2025 | Date of Form 4 filing |
Keywords
OnKure Therapeutics, OKUR, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Nicholas A. Saccomano, Corporate Officer, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.